In Q2 fiscal 2026 (the quarter ended June 30, 2026), Zimmer Biomet's largest product or service was Knees, with $828.90 million or 38% of revenue, up 0.4% from a year earlier. Next: SET (27%), Hips (26%) and Technology and Data, Bone Cement and Surgical (9%).
By region, Americas brought in 62%, EMEA brought in 22% and Asia Pacific brought in 16% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Technology and Data, Bone Cement and Surgical (+21.1%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Fiscal quarters, from company filings
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Knees | $828.9M | $828.6M | $792.4M | $826.0M | 38% |
| SET | $586.0M | $562.2M | $541.5M | $550.6M | 27% |
| Hips | $562.7M | $524.1M | $506.2M | $536.1M | 26% |
| Technology and Data, Bone Cement and Surgical | $199.4M | $171.8M | $161.3M | $164.6M | 9% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Americas | $1.4B | $1.3B | $1.3B | $1.3B | 62% |
| EMEA | $478.5M | $489.9M | $417.0M | $458.1M | 22% |
| Asia Pacific | $339.5M | $272.3M | $330.9M | $332.2M | 16% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Knees: $828.90 million, or 38% of revenue, in Q2 fiscal 2026.
By revenue in Q2 fiscal 2026: Knees (38%), SET (27%), Hips (26%) and Technology and Data, Bone Cement and Surgical (9%).
By region in Q2 fiscal 2026: Americas (62%), EMEA (22%) and Asia Pacific (16%).
Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i
Every item and period in one grid. Purple = calculated; "–" = not available.
| Item |
|---|